Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Publisher
Archivos de Cardiologia de Mexico(1)
Global Heart(1)
International Journal of Cardiology(1)
New England Journal of Medicine(1)
Área temáticas
Enfermedades(3)
Farmacología y terapéutica(3)
Medicina y salud(3)
Gestión y servicios auxiliares(1)
Problemas sociales y servicios a grupos(1)
Área de conocimiento
Enfermedad cardiovascular(4)
Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS)
ArticleAbstract: This is an executive summary made by a group of experts named Latin American Academy for the study oPalabras claves:Autores:Acevedo M., Alonso R., Arocha I., Bryce A., Carlos Ernesto Peñaherrera, Carrera C., Chirinos J.A., Cobos L., Colan J., Gómez-Alvares E., Gómez-M J.R., Isea-Perez J.E., Lanas F., Lara J., Lorenzatti A.J., Lozada A.F., Machado-H L.T., Medina J., Medina-Palomin F., Merchan-V A., Morales E., Paniagua M., PATRICIO LOPEZ -JARAMILLO, Pinto X., Piskorz D.L., Ponte-Negretti C.I., Ullauri V.E., Varleta P., Villar-M R.A., Wyss-Q F.S.Fuentes:scopusConsiderations and guidance for the structure, organisation, and operation of cardiometabolic prevention units: A consensus statement of the Inter-American Society of Cardiology
ArticleAbstract: Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, particularly in low- andPalabras claves:Cardiometabolic prevention unit, cardiometabolic risk, Cardiovascular preventionAutores:Barbosa E.C.D., Borrayo G., Cobos L., Gómez-Mancebo J.R., López-Santi R., Lorenzatti A.J., Machado L., PATRICIO LOPEZ -JARAMILLO, Piskorz D.L., Ponte-Negretti C.I., Puente-Barragan A., Ruiz E., Sosa-Liprandi Á., Valdéz O., Wyss F.S.Fuentes:googlescopusCardiovascular efficacy and safety of bococizumab in high-risk patients
ArticleAbstract: BACKGROUND Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilPalabras claves:Autores:Abbott J.D., Amarenco P., Anderson P., Baultrukonis D., Black H., Blake G., Borer J.S., Brunell R., Buonanno M., Carmena R., Chakrabarti A., Chaudhuri S., Chun H., Civeira F., Colquhoun D., Conde D., Cortada J.B., Curto M., Dan G.A., Dearborn-Tomazos J., Edes I., Epsley C., Evans B., Flather M., Foody J., Frederich R., Frolova M., Furie K.L., Gao R., Gelfand E., Glynn R.J., Goetsch M., Grégoire J., Grobbee D., Hessinger D., Hwang J.J., Jacoby D., Jadbabaie F., Jensen H.K., Johnson M., Jukema J.W., Kahan T., Karpov Y., Kastelein J.J.P., Koenig W., Lee C.W., Leiva Pons J.L., Lorenzatti A.J., Lotan C., Maggioni A.P., Manga P., Masiukiewicz U., McCullough L., McMurray J.J.V., McNamara R., McPherson C., Mellbin L., Miller M., Missault L., Montalescot G., Mosterd A., Mridha K., Murin J., Neaton J., Nicolau J.C., Nissen S.E., Noble S., O’Neill B., Piazza G., Pinto D., Ponikowski P., Powell C., Pride Y., Revkin J., Ridker P.M., Sandra Verónica Falconí Peláez, Sansing L.H., Santos R.D., Savolainen M., Savonitto S., Schiele F.N., Schindler J., Schwartz P.F., Shear C.L., Silverman I.E., Solar M., Soran H., Sritara P., Tarasenko L., Tardif J.C., Tökgozoğlu L., Urina M., Vrablik M., Wang E., Wei C., Welty F., White H.D., Wright R.S., Yunis C., Zannad F.Fuentes:googlescopusLatin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
ArticleAbstract: Background: Hypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chPalabras claves:Atherosclerotic cardiovascular disease, Cardiometabolic risk factors, Cardiovascular Risk, inflammation, Residual risk, ThrombosisAutores:Amaro A.J.J., Badimon J.J., Berrospi P., Bryce A., Cobos S. L., Duran M., Gómez-Mancebo J.R., González J.J.R., Lanas F.T., Lara J., Libby P., Lorenzatti A.J., Lozada A.F., Medina-Palomino F.A., Miranda D., PATRICIO LOPEZ -JARAMILLO, Piskorz D.L., Ponte-Negretti C.I., Puente-Barragan A., Rodrigo A.K., Santos R.D., Toth P.P., Ullauri-Solórzano V.E., Urina-Triana M., Valdés T.O., Villar R., Wyss F.S.Fuentes:scopus